This site is intended for U.S. healthcare professionals.

Visit Pfizer MedicalVisit Pfizer MedicalLoading

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient ProfilesPatient
ProfilesIdentifying PatientsUnmet NeedsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site
Eligible patients who may benefit from HYMPAVZIEligible patients who may benefit from HYMPAVZI

Do you have patients like these in your practice?

Do you have patients like these in your practice?

Patients with Hemophilia A without Inhibitors

Patients with Hemophilia B without Inhibitors

Tab Number 3

Tab Number 4

Tab Number 5

Gaining independence, wants 1 less “variable” Age: 17
  • In the last few years, he has switched to a new factor-based prophylaxis treatment to fit his lifestyle and provide bleed protection
  • Desires straightforward administration with minimal prep

Lifestyle Considerations

  • Participates in sports 
  • Wants to be self-sufficient, including with treatment* 
  • Caregiver is interested in a non-factor treatment option 

Why HYMPAVZI?

  • The HYMPAVZI pen is designed for ease of use. HYMPAVZI is available in a fixed-dose,† prefilled pen, which means consistent dosing with no mixing, measuring, or lengthy prep for your patients1
  • HYMPAVZI uses an innovative mechanism, targeting TFPI to help achieve hemostasis, offering your patients an alternative treatment approach1-4

Not an actual patient.

Wants to focus on personal pursuits Age: 60
  • Has been on routine factor-based prophylaxis treatment 
  • Starting to struggle with venous access 
  • Concerned about safety when it comes to treatment and interested in non-factor treatment options
Lifestyle Considerations
  • Wants to travel more 
  • Values his hobbies and playing with his grandkids 
Why HYMPAVZI?
  • The HYMPAVZI pen is designed for ease of use. HYMPAVZI is available in a fixed-dose,† prefilled pen, which means consistent dosing with no mixing, measuring, or lengthy prep for your patients1
  • HYMPAVZI uses an innovative mechanism, targeting TFPI to help achieve hemostasis, offering your patients an alternative treatment approach1-4

Not an actual patient.

Wants to focus on personal pursuits Age: 60
  • Has been on routine factor-based prophylaxis treatment 
  • Starting to struggle with venous access 
  • Concerned about safety when it comes to treatment and interested in non-factor treatment options
Lifestyle Considerations
  • Wants to travel more 
  • Values his hobbies and playing with his grandkids 
Why HYMPAVZI?
  • The HYMPAVZI pen is designed for ease of use. HYMPAVZI is available in a fixed-dose,† prefilled pen, which means consistent dosing with no mixing, measuring, or lengthy prep for your patients1
  • HYMPAVZI uses an innovative mechanism, targeting TFPI to help achieve hemostasis, offering your patients an alternative treatment approach1-4

Not an actual patient.

Unmet needs in hemophilia
LoadingUnmet needs in hemophiliaLoadingTFPI=tissue factor pathway inhibitor.HYMPAVZI is intended for use under the guidance of a healthcare provider. After proper training in subcutaneous injection technique, a patient may self-inject or the patient’s caregiver may administer HYMPAVZI, if a healthcare provider determines that it is appropriate.1 The recommended dosage of HYMPAVZI on day 1 is a loading dose of 300 mg (two 150 mg pens) by subcutaneous injection. On day 8 and thereafter, the weekly maintenance dose is 150 mg (one pen) by subcutaneous injection. A dose adjustment to 300 mg subcutaneous injection weekly can be considered in patients weighing ≥50 kg when control of bleeding events is judged to be inadequate by the healthcare provider. Safety and efficacy of HYMPAVZI at doses above 300 mg weekly have not been established.1 References:1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2024. 2. Srivastava A, et al. Haemophilia. 2020;26(suppl 6):1-158. 3. Butterfield JSS, et al. Mol Ther. 2020;28(3):997-1015. 4. Pittman DD, et al. Res Pract Thromb Haemost. 2022;6(2):e12679.
Ready for a change Age: 12
  • On routine prophylaxis and administers every 2 weeks. He does not time his infusions based on activities and has occasional breakthrough bleeds
  • Does not have the patience to prepare and sit through IV infusions
Lifestyle Considerations
  • Participates in sports like his peers 
  • Prefers to not see needle due to needle fear 
Why HYMPAVZI?
  • Once-weekly HYMPAVZI is the first and only subcutaneous prophylactic treatment for hemophilia A or B without inhibitors that comes in a fixed-dose,* prefilled pen with a hidden needle1-3

Not an actual patient.

Focusing on the next chapter in lifeAge: 30
  • On routine factor-based prophylaxis treatment; administers every 10 days
  • Frustrated with IV infusions
  • Growing family

Lifestyle Considerations
  • Busy with his work and family, finding time to infuse is hard. He wants to spend less time thinking about when to infuse and preparing for administration 
  • Interested in a prophylaxis treatment with straightforward administration 
Why HYMPAVZI?
  • Once-weekly HYMPAVZI is the first and only subcutaneous prophylactic treatment for hemophilia A or B without inhibitors that comes in a fixed-dose,* prefilled pen with a hidden needle1-3

Not an actual patient.

Focusing on the next chapter in lifeAge: 30
  • On routine factor-based prophylaxis treatment; administers every 10 days
  • Frustrated with IV infusions
  • Growing family

Lifestyle Considerations
  • Busy with his work and family, finding time to infuse is hard. He wants to spend less time thinking about when to infuse and preparing for administration 
  • Interested in a prophylaxis treatment with straightforward administration 
Why HYMPAVZI?
  • Once-weekly HYMPAVZI is the first and only subcutaneous prophylactic treatment for hemophilia A or B without inhibitors that comes in a fixed-dose,* prefilled pen with a hidden needle1-3

Not an actual patient.

Unmet needs in hemophilia
LoadingUnmet needs in hemophiliaLoadingThe recommended dosage of HYMPAVZI on day 1 is a loading dose of 300 mg (two 150 mg pens) by subcutaneous injection. On day 8 and thereafter, the weekly maintenance dose is 150 mg (one pen) by subcutaneous injection. A dose adjustment to 300 mg subcutaneous injection weekly can be considered in patients weighing ≥50 kg when control of bleeding events is judged to be inadequate by the healthcare provider. Safety and efficacy of HYMPAVZI at doses above 300 mg weekly have not been established.1 ​​​​​​References:1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2024. 2. Srivastava A, et al. Haemophilia. 2020;26(suppl 6):1-158. 3. Butterfield JSS, et al. Mol Ther. 2020;28(3):997-1015.
Patient ProfilesPatient Profiles Resources and support

Download educational resources that can support you and your patients

 See the resources Loading

HYMPAVZI is a trademark of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-HYM-USA-0073
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
 
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationHYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist and may increase the risk of thromboembolic complications. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).IndicationHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.